670 related articles for article (PubMed ID: 24716595)
1. Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis.
Horai Y; Koga T; Fujikawa K; Takatani A; Nishino A; Nakashima Y; Suzuki T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Ida H; Kakugawa T; Sakamoto N; Ishimatsu Y; Mukae H; Hamaguchi Y; Fujimoto M; Kuwana M; Origuchi T; Kohno S; Kawakami A
Mod Rheumatol; 2015 Jan; 25(1):85-9. PubMed ID: 24716595
[TBL] [Abstract][Full Text] [Related]
2. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM.
Koga T; Fujikawa K; Horai Y; Okada A; Kawashiri SY; Iwamoto N; Suzuki T; Nakashima Y; Tamai M; Arima K; Yamasaki S; Nakamura H; Origuchi T; Hamaguchi Y; Fujimoto M; Ishimatsu Y; Mukae H; Kuwana M; Kohno S; Eguchi K; Aoyagi K; Kawakami A
Rheumatology (Oxford); 2012 Jul; 51(7):1278-84. PubMed ID: 22378718
[TBL] [Abstract][Full Text] [Related]
3. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
Chen Z; Cao M; Plana MN; Liang J; Cai H; Kuwana M; Sun L
Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1316-24. PubMed ID: 23908005
[TBL] [Abstract][Full Text] [Related]
4. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
[TBL] [Abstract][Full Text] [Related]
5. Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis.
Nishioka A; Tsunoda S; Abe T; Yoshikawa T; Takata M; Kitano M; Matsui K; Nakashima R; Hosono Y; Ohmura K; Mimori T; Sano H
Mod Rheumatol; 2019 Sep; 29(5):814-820. PubMed ID: 30449228
[No Abstract] [Full Text] [Related]
6. Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis.
Takada T; Aoki A; Asakawa K; Sakagami T; Moriyama H; Narita I; Sato S
Respir Med; 2015 Sep; 109(9):1174-80. PubMed ID: 26187000
[TBL] [Abstract][Full Text] [Related]
7. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis.
Gono T; Sato S; Kawaguchi Y; Kuwana M; Hanaoka M; Katsumata Y; Takagi K; Baba S; Okamoto Y; Ota Y; Yamanaka H
Rheumatology (Oxford); 2012 Sep; 51(9):1563-70. PubMed ID: 22589330
[TBL] [Abstract][Full Text] [Related]
8. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.
Kobayashi N; Takezaki S; Kobayashi I; Iwata N; Mori M; Nagai K; Nakano N; Miyoshi M; Kinjo N; Murata T; Masunaga K; Umebayashi H; Imagawa T; Agematsu K; Sato S; Kuwana M; Yamada M; Takei S; Yokota S; Koike K; Ariga T
Rheumatology (Oxford); 2015 May; 54(5):784-91. PubMed ID: 25288783
[TBL] [Abstract][Full Text] [Related]
9. Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis.
Muro Y; Sugiura K; Akiyama M
Clin Rheumatol; 2013 Mar; 32(3):395-8. PubMed ID: 23250474
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum B-cell activating factor levels in patients with dermatomyositis: Association with interstitial lung disease.
Matsushita T; Kobayashi T; Kano M; Hamaguchi Y; Takehara K
J Dermatol; 2019 Dec; 46(12):1190-1196. PubMed ID: 31631384
[TBL] [Abstract][Full Text] [Related]
11. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.
Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
Arthritis Care Res (Hoboken); 2016 May; 68(5):689-94. PubMed ID: 26414240
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
[TBL] [Abstract][Full Text] [Related]
13. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis.
Gono T; Kawaguchi Y; Satoh T; Kuwana M; Katsumata Y; Takagi K; Masuda I; Tochimoto A; Baba S; Okamoto Y; Ota Y; Yamanaka H
Rheumatology (Oxford); 2010 Sep; 49(9):1713-9. PubMed ID: 20498012
[TBL] [Abstract][Full Text] [Related]
14. Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis.
Gono T; Kawaguchi Y; Ozeki E; Ota Y; Satoh T; Kuwana M; Hara M; Yamanaka H
Mod Rheumatol; 2011 Apr; 21(2):223-7. PubMed ID: 21052763
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report.
Endo Y; Koga T; Suzuki T; Hara K; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Umeda M; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kuwana M; Kawakami A
Medicine (Baltimore); 2018 Apr; 97(15):e0436. PubMed ID: 29642214
[TBL] [Abstract][Full Text] [Related]
16. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
[TBL] [Abstract][Full Text] [Related]
17. Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases.
Kawasumi H; Katsumata Y; Nishino A; Hirahara S; Kawaguchi Y; Kuwana M; Yamanaka H
J Rheumatol; 2018 Jul; 45(7):947-955. PubMed ID: 29657141
[TBL] [Abstract][Full Text] [Related]
18. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
Ye Y; Fu Q; Wang R; Guo Q; Bao C
J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
[TBL] [Abstract][Full Text] [Related]
19. Recurrence of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis after long-term remission: A case report.
Endo Y; Koga T; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Umeda M; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kuwana M; Hosono Y; Mimori T; Kawakami A
Medicine (Baltimore); 2018 Jun; 97(26):e11024. PubMed ID: 29952940
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis.
Xu Y; Yang CS; Li YJ; Liu XD; Wang JN; Zhao Q; Xiao WG; Yang PT
Clin Rheumatol; 2016 Jan; 35(1):113-6. PubMed ID: 26660480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]